Co. developing spinal-cord injury drug settles in Cambridge

BioAxone BioSciences yesterday celebrated the opening of its scientific and clinical headquarters at the Cambridge Innovation Center.

The company is developing a drug called Cethrin to reduce paralysis after a spinal cord injury by promoting the regrowth of broken fibers.

In its first clinical trial in patients, 31 percent of cervical spinal cord patients regained some motor function, with no serious adverse effects, said Lisa McKerracher, who started the company last year.

"We're very optimistic our next clinical trial will lead to drug approval," McKerracher said.

Traumatic spinal cord injury affects more than 12,000 Americans each year, mainly from motor vehicle accidents.

The only current treatment is surgery and rehabilitation.

"By treating patients with a drug like Cethrin and aggressive rehab," McKerracher said, "we hope we can start to make a difference."

Anda sedang membaca artikel tentang

Co. developing spinal-cord injury drug settles in Cambridge

Dengan url

http://terakhirjaman.blogspot.com/2012/11/co-developing-spinal-cord-injury-drug.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Co. developing spinal-cord injury drug settles in Cambridge

namun jangan lupa untuk meletakkan link

Co. developing spinal-cord injury drug settles in Cambridge

sebagai sumbernya